Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment
Sponsor: Daiichi Sankyo
Summary
A study to evaluate the long-term risk of hepatic failure with TURALIO™ (pexidartinib) and the mechanism of liver injury based upon optional liver biopsy information among patients who received or are receiving TURALIO™ (pexidartinib) and experience hepatotoxicity.
Official title: A Long-term Study to Further Evaluate the Risk of Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
30
Start Date
2021-01-07
Completion Date
2036-06-01
Last Updated
2025-10-06
Healthy Volunteers
No
Interventions
TURALIO™
This is a non-interventional, observational study to evaluate long-term risk of hepatic failure associated with TURALIO™ (pexidartinib) treatment. No study medication will be provided to the participants.
Locations (8)
Kamalesh K Sankhala MD INC
Santa Monica, California, United States
Sarcoma Oncology Research Center LLC
Santa Monica, California, United States
UCLA Hematology and Oncology
Santa Monica, California, United States
The Oncology Institute of Hope and Innovation
Whittier, California, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Montefiore Medical Center
New York, New York, United States
OSU - James Comprehensive Cancer Center
Columbus, Ohio, United States
Kelsey Seybold Clinic - Pearland
Houston, Texas, United States